Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06279104
Status:
RECRUITING
Last Update Posted:
2024-02-26
First Post:
2024-02-15
Brief Title:
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Sponsor:
Tongji Hospital
Organization:
Tongji Hospital
Study Overview
Official Title:
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this observational study is to learn about the treatment effectiveness of physicians choice of chemotherapy and the immune checkpoint inhibitor ICI-based therapy in patients with relapsedrefractory ovarian clear cell carcinoma OCCC and compare the treatment response with the phase II single-arm clinical trial INOVA to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab The main questions it aims to answer are
What is the efficacy of physicians choice of chemotherapy in relapsedrefractory OCCC patients in the real world
Is ICI-based therapy more effective than physicians choice of chemotherapy in real-world for relapsedrefractory OCCC patients
Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in RecurrentPersistent Ovarian Clear Cell Carcinoma INOVA trial more effective than physicians choice of chemotherapy
Participants will be respectively retrieved and extracted de-identified longitudinal electronic health records EHR-derived data
What is the efficacy of physicians choice of chemotherapy in relapsedrefractory OCCC patients in the real world
Is ICI-based therapy more effective than physicians choice of chemotherapy in real-world for relapsedrefractory OCCC patients
Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in RecurrentPersistent Ovarian Clear Cell Carcinoma INOVA trial more effective than physicians choice of chemotherapy
Participants will be respectively retrieved and extracted de-identified longitudinal electronic health records EHR-derived data
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None